None

Proposed omalizumab guidance changes spark concerns

Draft guidance advising against the use of omalizumab has been published by the National Institute for Health and Clinical Excellence...

Omalizumab meets primary in Phase III for chronic idiopathic urticaria

Novartis AG (NYSE:NVS; SIX:NOVN) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said subcutaneous omalizumab given every four weeks for 12 weeks as an add-on to antihistamine therapy met...

Omalizumab scratches the itch for urticaria patients

The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers.

Omalizumab May Help Kids With Uncontrolled Allergic Asthma

Children with severe refractory allergic asthma may benefit from adding omalizumab (Xolair, Roche/Genentech, Novartis), French clinicians say. Reuters Health Information

Omalizumab effective for nasal polyps in patients with asthma

NEW YORK (Reuters Health) - Omalizumab helps treat nasal polyps in patients with asthma, whether or not they suffer from allergies.

Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic ...

Study published in NEJM today and presented tomorrow met primary endpoint[1] in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) Up to two-thirds (66%) of omal...

Genentech Ph III study of omalizumab shows promise in CIU

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase III trial, ASTERIA II, which demonstrated that omalizumab met its primary endpoint in patients...

NICE Consults on Treatment for Asthma in Children and Adults

In draft guidance published today (9 November), NICE has not recommended omalizumab (Xolair, Novartis Pharmaceuticals UK) for treating severe, persistent allergic asthma in adults and children. Peopl...

Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions.

Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly a subset of asthmatics patients with inadequately controlled moderate-to-severe persis...

Measured Immunoglobulin E in Allergic Bronchopulmonary Aspergillosis Treated With Omalizumab.

Background. The ability to assess adequate reductions in immunoglobulin E (IgE) in allergic bronchopulmonary aspergillosis (ABPA) has been a concern with regards to omalizumab treatment. Objective. To...

THE EFFICACY OF SHORTENING AN ADMINISTRATION PERIOD WITH OMALIZUMAB.

A 64-year old male who had been treated with oral predisolone for severe bronchial asthma had started the treatment of omalizumab administration every 4 weeks since December 2009 and his symptoms had...

Anti-IgE - emerging opportunities for Omalizumab.

Introduction: Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to free and membrane-bound immunoglobulin E (IgE) antibodies. Omalizumab has been licens...

Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.

BACKGROUND: Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal ant...